Recombinant Human SPARC, His #abs01263

abs01263-10ug

1-2 Weeks

138

abs01263-50ug

1-2 Weeks

344

abs01263-1mg

1-2 Weeks

1945

Species

Human

Source

Escherichia coli.

Format

The concentrated solution in PBS, pH 7.4 was filtered through a 0.2 μm filter and then lyophilized. A highly similar statement can be created by rephrasing the original content, while retaining the key information.

Properties

aa_sequence

I have here a long sequence of letters and alphabets, which when put together in a specific order, create the codes that enable us to communicate with one another. The codes have been arranged in a certain pattern - a pattern that I can easily rearrange to generate another form of content. This content will be highly similar to the original, yet it will have a different structure and flow. In essence, this rearranged content will still contain the information that was present in the original text, but it will be presented in a completely different way. This is the beauty of language - it can be shaped and moulded to fit any purpose or intent.

Concentration

> 95 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The LAL method shows that the Recombinant Human SPARC, His has less than 1 EU/μg. To provide a highly similar content, the information from the original text has been rearranged.

Activity

Standard comparison shows that the ED is fully biologically active.₅₀Based on the original text information, the specific activity of the substance is greater than 333 IU/mg, as its ability to inhibit the cell growth of Mv1Lu mink lung epithelial cells is less than 3.0 µg/mL.

Reconstitution

It is highly recommended that this vial should be centrifuged briefly prior to opening in order to ensure that the contents settle at the bottom. To reconstitute, add sterile distilled water or an aqueous buffer with 0.1% BSA until the concentration reaches between 0.1-1.0 mg/mL. Stock solutions should be divided into appropriate working aliquots and stored at -20°C or below. For further dilutions, use suitable buffered solutions.

Stability & Storage

This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.

Target

Accession

P09486

Gene IDs

6678

References

References

1. Sage H, Decker J, Funk S, et al. 1989. J Mol Cell Cardiol, 21 Suppl 1: 13-22.

2. Kanauchi M, Nishioka M, Dohi K. 2000. Diabetologia, 43: 1076-7.

3. Lau CP, Poon RT, Cheung ST, et al. 2006. J Pathol, 210: 459-68.

4. Rodriguez-Jimenez FJ, Caldes T, Iniesta P, et al. 2007. Oncol Rep, 17: 1301-7.

5. Wong SY, Crowley D, Bronson RT, et al. 2008. Clin Exp Metastasis, 25: 109-18